Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.56 |
| ▸ | MERTK | Q12866 | 3/20 | 0.49 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.43 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10217502 | 0.84 | MET (0.62) | METMERTKAXLLRRK2MBTD1 | |
| SCHEMBL10217475 | 0.84 | MET (0.62) | METMERTKAXLLRRK2ATR | |
| SCHEMBL10217473 | 0.84 | MET (0.56) | METMERTKAXLLRRK2ATR | |
| SCHEMBL10217465 | 0.84 | MET (0.57) | METMERTKAXLLRRK2ATR | |
| SCHEMBL487790 | 0.83 | MET (0.68) | METMERTKAXLLRRK2ATR | |
| SCHEMBL10217507 | 0.83 | MET (0.62) | METMERTKAXLLRRK2MBTD1 | |
| SCHEMBL488391 | 0.83 | MET (0.68) | METMERTKAXLLRRK2ATR | |
| SCHEMBL30453080 | 0.83 | MET (0.68) | METMERTKAXLLRRK2ATR | |
| SCHEMBL488613 | 0.82 | MET (0.66) | METMERTKAXLATRMBTD1 | |
| SCHEMBL10217969 | 0.82 | MET (0.57) | METMERTKAXLATRMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | MET 1/4885MERTK 69/4885AXL 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.